What is the current valuation of the infectious vaccines market as of 2024?

The infectious vaccines market was valued at 65.0 USD Billion in 2024. Read More

What is the projected market valuation for the infectious vaccines market in 2035?

The market is projected to reach 100.0 USD Billion by 2035. Read More

What is the expected compound annual growth rate (CAGR) for the infectious vaccines market from 2025 to 2035?

The expected CAGR for the infectious vaccines market during the forecast period 2025 - 2035 is 3.99%. Read More

Which companies are considered key players in the infectious vaccines market?

Key players in the market include Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Sanofi, GlaxoSmithKline, Merck & Co., Novavax, Bharat Biotech, and Sinovac Biotech. Read More

How much revenue is generated from preventive vaccines in the infectious vaccines market?

Preventive vaccines generated revenue between 30.0 and 45.0 USD Billion. Read More

What is the revenue range for viral infections in the infectious vaccines market?

Revenue from viral infections is projected to range between 25.0 and 40.0 USD Billion. Read More

Which end-use segments are prominent in the infectious vaccines market?

Prominent end-use segments include Hospitals, Clinics, Pharmacies, and Public Health Organizations. Read More

What routes of administration are utilized for vaccines in the infectious vaccines market?

Vaccines are administered through Intramuscular, Subcutaneous, Oral, and Intranasal routes. Read More

Infectious Vaccines Market

Q: What are the main segments of the infectious vaccines market by application?

The main segments by application include Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Pediatric Vaccines. Read More

Q: What types of vaccines are included in the technology segment of the infectious vaccines market?

The technology segment includes Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and mRNA Vaccines. Read More

ID: MRFR/HC/65250-HCR

200 Pages

Satyendra Maurya

Last Updated: March 15, 2026

Infectious Vaccines Market Research Report: Size, Share, Trend Analysis By End Use (Hospitals, Clinics, Pharmacies, Public Health Organizations), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Pediatric Vaccines), By Target Pathogen (Bacterial Infections, Viral Infections, Parasitic Infections, Fungal Infections), By Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal) – Growth Outlook & Industry Forecast To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Application (USD Billion)
4.1.1 Preventive Vaccines
4.1.2 Therapeutic Vaccines
4.1.3 Travel Vaccines
4.1.4 Pediatric Vaccines
4.2 Healthcare, BY Technology (USD Billion)
4.2.1 Live Attenuated Vaccines
4.2.2 Inactivated Vaccines
4.2.3 Subunit Vaccines
4.2.4 mRNA Vaccines
4.3 Healthcare, BY End Use (USD Billion)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Pharmacies
4.3.4 Public Health Organizations
4.4 Healthcare, BY Route of Administration (USD Billion)
4.4.1 Intramuscular
4.4.2 Subcutaneous
4.4.3 Oral
4.4.4 Intranasal
4.5 Healthcare, BY Target Pathogen (USD Billion)
4.5.1 Bacterial Infections
4.5.2 Viral Infections
4.5.3 Parasitic Infections
4.5.4 Fungal Infections
4.6 Healthcare, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Pfizer (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Moderna (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Johnson & Johnson (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 AstraZeneca (GB)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Sanofi (FR)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 GlaxoSmithKline (GB)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Merck & Co. (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Novavax (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Bharat Biotech (IN)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.2.10 Sinovac Biotech (CN)
5.2.10.1 Financial Overview
5.2.10.2 Products Offered
5.2.10.3 Key Developments
5.2.10.4 SWOT Analysis
5.2.10.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY APPLICATION
6.4 US MARKET ANALYSIS BY TECHNOLOGY
6.5 US MARKET ANALYSIS BY END USE
6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.7 US MARKET ANALYSIS BY TARGET PATHOGEN
6.8 CANADA MARKET ANALYSIS BY APPLICATION
6.9 CANADA MARKET ANALYSIS BY TECHNOLOGY
6.10 CANADA MARKET ANALYSIS BY END USE
6.11 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.12 CANADA MARKET ANALYSIS BY TARGET PATHOGEN
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY APPLICATION
6.15 GERMANY MARKET ANALYSIS BY TECHNOLOGY
6.16 GERMANY MARKET ANALYSIS BY END USE
6.17 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.18 GERMANY MARKET ANALYSIS BY TARGET PATHOGEN
6.19 UK MARKET ANALYSIS BY APPLICATION
6.20 UK MARKET ANALYSIS BY TECHNOLOGY
6.21 UK MARKET ANALYSIS BY END USE
6.22 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.23 UK MARKET ANALYSIS BY TARGET PATHOGEN
6.24 FRANCE MARKET ANALYSIS BY APPLICATION
6.25 FRANCE MARKET ANALYSIS BY TECHNOLOGY
6.26 FRANCE MARKET ANALYSIS BY END USE
6.27 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.28 FRANCE MARKET ANALYSIS BY TARGET PATHOGEN
6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
6.30 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
6.31 RUSSIA MARKET ANALYSIS BY END USE
6.32 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.33 RUSSIA MARKET ANALYSIS BY TARGET PATHOGEN
6.34 ITALY MARKET ANALYSIS BY APPLICATION
6.35 ITALY MARKET ANALYSIS BY TECHNOLOGY
6.36 ITALY MARKET ANALYSIS BY END USE
6.37 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.38 ITALY MARKET ANALYSIS BY TARGET PATHOGEN
6.39 SPAIN MARKET ANALYSIS BY APPLICATION
6.40 SPAIN MARKET ANALYSIS BY TECHNOLOGY
6.41 SPAIN MARKET ANALYSIS BY END USE
6.42 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.43 SPAIN MARKET ANALYSIS BY TARGET PATHOGEN
6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
6.45 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
6.46 REST OF EUROPE MARKET ANALYSIS BY END USE
6.47 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.48 REST OF EUROPE MARKET ANALYSIS BY TARGET PATHOGEN
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY APPLICATION
6.51 CHINA MARKET ANALYSIS BY TECHNOLOGY
6.52 CHINA MARKET ANALYSIS BY END USE
6.53 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.54 CHINA MARKET ANALYSIS BY TARGET PATHOGEN
6.55 INDIA MARKET ANALYSIS BY APPLICATION
6.56 INDIA MARKET ANALYSIS BY TECHNOLOGY
6.57 INDIA MARKET ANALYSIS BY END USE
6.58 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.59 INDIA MARKET ANALYSIS BY TARGET PATHOGEN
6.60 JAPAN MARKET ANALYSIS BY APPLICATION
6.61 JAPAN MARKET ANALYSIS BY TECHNOLOGY
6.62 JAPAN MARKET ANALYSIS BY END USE
6.63 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.64 JAPAN MARKET ANALYSIS BY TARGET PATHOGEN
6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
6.66 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
6.67 SOUTH KOREA MARKET ANALYSIS BY END USE
6.68 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.69 SOUTH KOREA MARKET ANALYSIS BY TARGET PATHOGEN
6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
6.71 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
6.72 MALAYSIA MARKET ANALYSIS BY END USE
6.73 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.74 MALAYSIA MARKET ANALYSIS BY TARGET PATHOGEN
6.75 THAILAND MARKET ANALYSIS BY APPLICATION
6.76 THAILAND MARKET ANALYSIS BY TECHNOLOGY
6.77 THAILAND MARKET ANALYSIS BY END USE
6.78 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.79 THAILAND MARKET ANALYSIS BY TARGET PATHOGEN
6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
6.81 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
6.82 INDONESIA MARKET ANALYSIS BY END USE
6.83 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.84 INDONESIA MARKET ANALYSIS BY TARGET PATHOGEN
6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
6.86 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
6.87 REST OF APAC MARKET ANALYSIS BY END USE
6.88 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.89 REST OF APAC MARKET ANALYSIS BY TARGET PATHOGEN
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
6.92 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
6.93 BRAZIL MARKET ANALYSIS BY END USE
6.94 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.95 BRAZIL MARKET ANALYSIS BY TARGET PATHOGEN
6.96 MEXICO MARKET ANALYSIS BY APPLICATION
6.97 MEXICO MARKET ANALYSIS BY TECHNOLOGY
6.98 MEXICO MARKET ANALYSIS BY END USE
6.99 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.100 MEXICO MARKET ANALYSIS BY TARGET PATHOGEN
6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
6.102 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
6.103 ARGENTINA MARKET ANALYSIS BY END USE
6.104 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.105 ARGENTINA MARKET ANALYSIS BY TARGET PATHOGEN
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATHOGEN
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
6.113 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
6.114 GCC COUNTRIES MARKET ANALYSIS BY END USE
6.115 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.116 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATHOGEN
6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
6.118 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
6.119 SOUTH AFRICA MARKET ANALYSIS BY END USE
6.120 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.121 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATHOGEN
6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
6.123 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
6.124 REST OF MEA MARKET ANALYSIS BY END USE
6.125 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.126 REST OF MEA MARKET ANALYSIS BY TARGET PATHOGEN
6.127 KEY BUYING CRITERIA OF HEALTHCARE
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF HEALTHCARE
6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
6.135 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
6.136 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
6.137 HEALTHCARE, BY END USE, 2024 (% SHARE)
6.138 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
6.139 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
6.140 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.141 HEALTHCARE, BY TARGET PATHOGEN, 2024 (% SHARE)
6.142 HEALTHCARE, BY TARGET PATHOGEN, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
7.2.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.2.3 BY END USE, 2025-2035 (USD Billion)
7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.2.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
7.3.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.3.3 BY END USE, 2025-2035 (USD Billion)
7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
7.4.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.4.3 BY END USE, 2025-2035 (USD Billion)
7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
7.5.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.5.3 BY END USE, 2025-2035 (USD Billion)
7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
7.6.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.6.3 BY END USE, 2025-2035 (USD Billion)
7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
7.7.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.7.3 BY END USE, 2025-2035 (USD Billion)
7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
7.8.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.8.3 BY END USE, 2025-2035 (USD Billion)
7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
7.9.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.9.3 BY END USE, 2025-2035 (USD Billion)
7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
7.10.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.10.3 BY END USE, 2025-2035 (USD Billion)
7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
7.11.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.11.3 BY END USE, 2025-2035 (USD Billion)
7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
7.12.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.12.3 BY END USE, 2025-2035 (USD Billion)
7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
7.13.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.13.3 BY END USE, 2025-2035 (USD Billion)
7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
7.14.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.14.3 BY END USE, 2025-2035 (USD Billion)
7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
7.15.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.15.3 BY END USE, 2025-2035 (USD Billion)
7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
7.16.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.16.3 BY END USE, 2025-2035 (USD Billion)
7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
7.17.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.17.3 BY END USE, 2025-2035 (USD Billion)
7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
7.18.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.18.3 BY END USE, 2025-2035 (USD Billion)
7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
7.19.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.19.3 BY END USE, 2025-2035 (USD Billion)
7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
7.20.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.20.3 BY END USE, 2025-2035 (USD Billion)
7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
7.21.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.21.3 BY END USE, 2025-2035 (USD Billion)
7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
7.22.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.22.3 BY END USE, 2025-2035 (USD Billion)
7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
7.23.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.23.3 BY END USE, 2025-2035 (USD Billion)
7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
7.24.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.24.3 BY END USE, 2025-2035 (USD Billion)
7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
7.25.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.25.3 BY END USE, 2025-2035 (USD Billion)
7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
7.26.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.26.3 BY END USE, 2025-2035 (USD Billion)
7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
7.27.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.27.3 BY END USE, 2025-2035 (USD Billion)
7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
7.28.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.28.3 BY END USE, 2025-2035 (USD Billion)
7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
7.29.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.29.3 BY END USE, 2025-2035 (USD Billion)
7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
7.30.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
7.30.3 BY END USE, 2025-2035 (USD Billion)
7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30.5 BY TARGET PATHOGEN, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Pediatric Vaccines

Healthcare By Technology (USD Billion, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
mRNA Vaccines

Healthcare By End Use (USD Billion, 2025-2035)

Hospitals
Clinics
Pharmacies
Public Health Organizations

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intramuscular
Subcutaneous
Oral
Intranasal

Healthcare By Target Pathogen (USD Billion, 2025-2035)

Bacterial Infections
Viral Infections
Parasitic Infections
Fungal Infections

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓